Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
PK and PD of a new beclomethasone dipropionate and formoterol CFC-free fixed combination Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Pharmacokinetic and pharmacodinamic effect of AeroChamber Plus spacer on the Extrafine beclometasone dipropionate plus formoterol combination (200/6 µg) Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide™) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019 Year: 2020
Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide? Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients Source: Eur Respir J 2005; 26: Suppl. 49, 180s Year: 2005
Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg Source: International Congress 2017 – Inhalers and their use Year: 2017